Phase 3 Chronic Kidney Disease Trial, Recruiting NCT05732727 Sponsor: University Hospital, Tours Condition: Chronic Kidney Disease
Back to Chronic Kidney Disease

Phase 3 Chronic Kidney Disease Trial, Recruiting

NCT05732727
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years old or older (if you are over 80, you must also be assessed as not severely frail, based on a standard frailty scoring tool)
  • You have moderate or advanced chronic kidney disease, based on a specific kidney function measurement (eGFR between 15 and 44.9, confirmed by a blood test)
  • You have high blood pressure that is being treated with at least one blood pressure-lowering medicine from a specific group of drugs (called ACE inhibitors or ARBs), at the highest dose you can tolerate, and your treatment has been stable for at least one month
  • Your blood pressure is still not well controlled, shown by readings taken both at a clinic and at home or during a 24-hour blood pressure monitoring test
  • You are covered by or entitled to social security
  • You are willing and able to give written consent to take part

Who may not be able to join:

  • You are currently subject to any form of legal guardianship or protection order
  • You are pregnant or breastfeeding
  • You are a woman who could become pregnant and are not using a highly effective form of contraception (such as hormonal contraception that stops ovulation, a coil/IUD, or a hormonal intrauterine device)
  • You show signs of being significantly dehydrated or low on body fluids
  • You experience dizziness or faintness when standing up due to low blood pressure
  • Your blood sodium level is too low (below 130 mmol/L, confirmed by a blood test)
  • Your blood potassium level is too low or too high (outside the range of 3.5–5.5 mmol/L, confirmed by a blood test)
  • You have had a serious heart or stroke event in the last three months, such as a heart attack, a hospital stay for heart failure, or a stroke
  • You are currently receiving chemotherapy for cancer
  • You have had an organ transplant (such as a kidney, liver, or heart transplant)
  • You are already taking two or more types of water tablet (diuretic) medicines at the same time
  • You are currently taking a type of medicine called a mineralocorticoid receptor antagonist (such as spironolactone) (confirm with trial site)
  • You have a specific inherited kidney condition called autosomal dominant polycystic kidney disease and are being treated with a medicine called Tolvaptan
  • You have a medical reason why you cannot take certain water tablet (diuretic) medicines used in this trial (confirm with trial site)
  • You have severe heart failure (confirm with trial site)
  • You have advanced liver cirrhosis (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Bénédicte Sautenet, MD, University Hospital, Tours

Phone: 02.34.37.96.86

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
University Hospital, Tours
Registry
ClinicalTrials.gov
Start date
28 March 2023
Est. completion
1 March 2029

Where this trial is recruiting

🇫🇷 France

Primary endpoints

End stage kidney disease; eGFR decline of at least 40%; Cardiovascular events; All cause mortality

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov